Technical Analysis for TRDA - Entrada Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 18.35 | 2.34% | 0.42 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 2.34% | |
| Narrow Range Bar | Range Contraction | 2.34% | |
| Oversold Stochastic | Weakness | 2.34% | |
| Stochastic Reached Oversold | Weakness | 3.26% | |
| Oversold Stochastic | Weakness | 3.26% | |
| 20 DMA Resistance | Bearish | 5.16% | |
| New Downtrend | Bearish | 5.16% | |
| Down 3 Days in a Row | Weakness | 5.16% | |
| Fell Below 20 DMA | Bearish | 2.80% | |
| MACD Bearish Signal Line Cross | Bearish | 2.80% |
| Alert | Time |
|---|---|
| Up 2% | about 1 hour ago |
| Rose Above 20 DMA | about 1 hour ago |
| Up 1% | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 3 hours ago |
| Down 1% | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/06/2024
Entrada Therapeutics, Inc. Description
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Disease Medical Genetics Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Genetic Genealogy Myotonic Dystrophy Neuromuscular Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.49 |
| 52 Week Low | 10.95 |
| Average Volume | 142,490 |
| 200-Day Moving Average | 15.19 |
| 50-Day Moving Average | 16.93 |
| 20-Day Moving Average | 18.21 |
| 10-Day Moving Average | 18.87 |
| Average True Range | 0.84 |
| RSI (14) | 49.75 |
| ADX | 25.94 |
| +DI | 21.86 |
| -DI | 23.66 |
| Chandelier Exit (Long, 3 ATRs) | 17.96 |
| Chandelier Exit (Short, 3 ATRs) | 19.34 |
| Upper Bollinger Bands | 20.29 |
| Lower Bollinger Band | 16.13 |
| Percent B (%b) | 0.43 |
| BandWidth | 22.86 |
| MACD Line | 0.35 |
| MACD Signal Line | 0.56 |
| MACD Histogram | -0.2041 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.56 | ||||
| Resistance 3 (R3) | 18.49 | 18.22 | 18.46 | ||
| Resistance 2 (R2) | 18.22 | 18.06 | 18.25 | 18.42 | |
| Resistance 1 (R1) | 18.07 | 17.96 | 18.15 | 18.14 | 18.38 |
| Pivot Point | 17.80 | 17.80 | 17.83 | 17.83 | 17.80 |
| Support 1 (S1) | 17.65 | 17.64 | 17.73 | 17.72 | 17.48 |
| Support 2 (S2) | 17.38 | 17.54 | 17.41 | 17.44 | |
| Support 3 (S3) | 17.23 | 17.38 | 17.41 | ||
| Support 4 (S4) | 17.30 |
